A year ago, the heart evidence for vitamin K2 looked intriguing but unproven — the field was waiting on a bigger, cleaner trial before anyone got excited. That trial has now landed, and it did exactly what supporters hoped: the vitamin K2 group built up less calcium in their arteries than the placebo group [1].
It sounds like a clear win. Read the study carefully, though, and the sensible response is more caution, not less. Here's what the new trial actually shows — and where the honest limits are.
Table of Contents
- First, clearing up the biggest myth
- The trial that got stronger
- A number is not an outcome
- The calcium paradox
- Bone — the more reasonable case
- The catch nobody mentions
- A sensible dose, and one safety point
- References
First, clearing up the biggest myth
Before the trial, one common belief is worth clearing up: that vitamin K2 only works, or won't backfire, if it's taken alongside vitamin D and magnesium. That idea is overblown. Getting good amounts of vitamin D and magnesium — the same as any other vitamin or mineral — is enough, and there's no need to megadose them.
In fact, the strongest trial for K2 and the heart used K2 on its own. So the myth clears quickly, and the trial can speak for itself.
The trial that got stronger
Researchers gave 360 micrograms of K2, on its own, every day for two years, to people who already had calcium building up in their coronary arteries [1] — an important detail, because these participants already had diseased blood vessels.
Over those two years, the calcium score rose in everyone, but it climbed less in the K2 group: the calcium score rose about 36% on K2 versus 48% on placebo, and the mass of calcium — a more reliable measure — rose 7 milligrams on K2 versus 12 on placebo [2].
That consistency matters. A calcium score can be jumpy, wobbling depending on how a scan picks up dense flecks, so the fact that the calcium mass moved in the same direction is reassuring — it suggests this isn't a quirk of one measurement method.
A blood marker confirming that K2 had switched on the system it targets also moved the right way. So the mechanism fired: the K2 got in, did its job, and the calcium climbed more slowly. Three separate signals lined up — as a piece of biology, it's clean.
This is a real step up from a year earlier. The trial before it was Danish, and it was null overall, showing a benefit only in the people who already had the most calcium [3]. The new one is cleaner: pure K2, both men and women, a result across the whole group rather than one slice.
But does that settle the question of taking K2 for the heart? No. The honest catch arrives in the same breath as the good news. The authors themselves call the effect "modest." And one number inside the trial matters: among the fast progressors — the people whose calcium was racing ahead — K2 did not cut that group down. The share of fast progressors was basically the same in both groups [1].
The positive trial also doesn't stand alone. It sits among trials where K2 did nothing: in people with type-2 diabetes, nothing [4]; in people with kidney disease, nothing, including one trial at a 90-microgram dose [5][6]. Read together, a pattern appears: K2 seems to slow calcium build-up in people who already have calcium quietly accumulating — not a "take it and stay clean" pill. Even on the best reading, though, a bigger problem waits underneath.
A number is not an outcome
Slowing a calcium score is not the same as preventing a heart attack. A higher calcium score does track with higher risk, but it is a measurement on a scan, not an event. And no K2 trial has ever shown fewer heart attacks or fewer deaths.
The one trial that did look at hard outcomes — heart attacks and deaths, in dialysis patients — found no difference [7]. It was small and in a specific population, so it doesn't close the door, but it's the only hard-outcome trial available, and it came back empty.
Still, surely less calcium is better than more? That feels obvious — and it's exactly where the story turns strange.
The calcium paradox
Picture plaque in an artery wall: a soft, inflamed, greasy pocket — the dangerous kind. The danger isn't the calcium itself; it's that pocket bursting open and triggering a clot.
When the body can't fully heal a wound, it walls it off, laying down hard calcium over the top like a shell or a scar. That dense calcium isn't the bomb — it's the casing around the bomb, holding the dangerous material shut. In other words, the body deposits calcium to try to stabilise the plaque.
That sharpens the unsettling question. If K2 slows the calcium down, is it also slowing plaque stabilisation — leaving vulnerable plaque more likely to rupture? A single total number on a scan can't separate those two possibilities. It counts the calcium; it doesn't say whose side it's on. Which is why hard-outcome data matters — what happens to heart attack rates, not just to a scan.
There's a real, well-known example that flips the obvious intuition. Statins are among the best-proven medicines for cutting heart attacks and deaths — and they actually increase the calcium in arteries, hardening plaque into solid, stable scar tissue, while patients do better [8].
So a drug that adds calcium to arteries saves lives. "More calcium on the scan" can be the good direction in the right context — which means moving calcium the other way, slowing it down, could just as easily be neutral, helpful, or quietly harmful. Genuinely, no one knows which.
An important caution here, because this is where the story gets twisted into a scare: K2 is not stripping calcium out of the stable scar tissue already built. It's slowing new calcium forming in plaques still developing. Those may be two completely different things. Slowing the new stuff might be fine, or even good — but it might not be.
And the new trial can't answer that, because it didn't look: it measured the calcium, but not the soft, dangerous non-calcified plaque — not how much there was, or whether it grew more stable or less [1].
So the headline — "K2 slows artery calcium" — is true. But the question that decides whether it matters — "is that good for the heart?" — is wide open. On the current evidence, there isn't a compelling reason to take vitamin K2 for heart health. The other half of the K2 story, though, is bone.
Bone — the more reasonable case
For anyone taking K2, bone is where the evidence is most reasonable — more reasonable than the heart. There's some decent trial evidence that K2 slows the loss of bone density with age: the best single trial used 180 micrograms a day over three years and modestly slowed the decline in bone density at the spine and hip [9].
But the line that decides the bone question is this: improving bone density is not the same as preventing a fracture. Density is a number on a scan; a fracture is what breaks a hip and changes a life. And looking specifically at fractures, K2 hasn't been shown to reduce them [10].
So bone lands the same shape as the heart: some evidence for density, none so far for fractures. It's the most reasonable reason to take K2 — and it still carries a caveat. For anyone who has weighed all of that and still wants to try it, two practical things matter, and the first is rarely discussed.
The catch nobody mentions — K2 falls apart unless it's protected
A lot of the K2 on shelves isn't fully there by the time it's swallowed. The form used across these trials is MK-7, and MK-7 is fragile: over time it flips from its active form into an inactive one — same molecule, wrong shape, no effect. That breakdown speeds up when K2 is packed into the same pill as minerals like calcium and magnesium.
This isn't theoretical. When an independent lab tested popular K2 products, some carried only a fraction of the labelled amount — one well-known product had barely a third of its claimed K2 [2].
The manufacturing fix is a protected, encapsulated form, coated so it survives sitting next to those minerals without breaking down. Even when a label claims an encapsulated form, it's worth verifying against third-party testing sites such as consumerlab.com or labdoor.com. Once the K2 content is confirmed, the remaining questions are dose and one safety point.
A sensible dose, and one safety point
On dose: the trial numbers sound large — 180, 360, even 720 micrograms — but there's no recognised recommended daily requirement for vitamin K2 (for vitamin K1 it's 120 micrograms). A sensible supplement dose is genuinely hard to pin down, because the data isn't there.
The doses in these studies range from 180 to 360 micrograms. No upper safe limit has ever been set for K2, and the longest trials ran only three years — so no one knows what taking 360 micrograms a day for, say, twenty years does. A more conservative strategy is something like 90 micrograms a day: enough to cover adequacy without betting decades on high experimental amounts that haven't been checked for long-term safety. To be clear about what 90 micrograms is and isn't — it's a cautious, adequacy-based choice, not "the dose proven to slow calcium." The trials that moved the scan used more. Anyone claiming 90 micrograms is a clinically proven heart dose is going beyond the evidence.
On safety: for people on warfarin — the older blood thinner that needs regular blood tests — vitamin K2 calls for real caution. Vitamin K works directly against warfarin, and MK-7 does so even at tiny doses because it lingers in the body for days; some experts advise warfarin patients to avoid it entirely [2].
One reassurance: this is specifically a warfarin issue. Aspirin and the newer blood thinners — apixaban, dabigatran, and rivaroxaban — are not affected.
Overall, the new trial is tentatively positive. There's a theoretical possibility that vitamin K2 could even worsen heart attack rates, and what's needed next is a trial measuring hard outcomes like heart attacks and strokes. Until then, careful dosing and third-party-tested products are the sensible path. The evidence got stronger — and the reasonable response is more caution, not less. "Slows a calcium score" and "prevents a heart attack" are two different sentences, and anyone selling the second is well ahead of the data.
References
1. https://doi.org/10.1001/jamacardio.2026.1279
2. https://www.consumerlab.com/reviews/vitamin-k-supplements-review/vitamin-k/
3. https://doi.org/10.1016/j.jacadv.2023.100643
4. https://doi.org/10.1093/ajcn/nqy373
5. https://doi.org/10.1681/ASN.2020020225
6. https://doi.org/10.20452/pamw.3041
7. https://pubmed.ncbi.nlm.nih.gov/37705910/
8. https://doi.org/10.1016/j.jacc.2015.01.036
